All In Biotech

Drug Trial Radar · NCT04984668

A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors

A Phase Ib/II, Multicenter Study of GT90001 in Combination With KN046 in Patients With Advanced or Refractory Solid Tumors

Last checked: Nov 19, 2026Latest source record: Feb 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

216

Planned (sponsor's estimate)

Start

Nov 2, 2021

Primary completion

Apr 2025

Study completion Dec 2025

Sponsor

Sponsor type
Industry
Collaborators
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
First posted
Jul 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase Ib is a dose De-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of GT90001 in combination with KN046 in subjects with advanced or refractory hepatocellular carcinoma (HCC), gastric carcinoma (GC) and gastroesophageal junction (GEJ) adenocarcinoma, urothelial carcinoma (UC) and esophageal square cell carcinoma (ESCC). Phase II is to investigate anti-tumor efficacy of GT90001 in combination with KN046 at RP2D in subjects with specific types of tumors. A Simon two-stage design is planned for each indication in order to minimize the number of treated participants if there is minimal efficacy activity in that indication.

Conditions

  • Solid Tumor

Interventions

  • GT90001+KN046Drug

    GT90001 7.0mg/Kg, KN046 5mg/Kg

  • GT90001+KN046Drug

    GT90001 7.0mg/Kg , KN046 3mg/Kg

  • GT90001/KN046Drug

    GT90001 4.5mg/Kg / KN046 5mg/Kg

  • GT90001+KN046Drug

    GT90001 4.5mg/Kg, KN046 3mg/Kg

  • GT90001+KN046Drug

    GT90001 3mg/Kg , KN046 3mg/Kg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse events (TEAEs), treatment-related AEs (TRAEs), serious adverse events (SAEs), Dose Limiting Toxicities (DLTs)Time frame: until progression or death,whichever came first, assessed up to 2 years
  2. Phase 2 dose (RP2D) of GT90001 in combination with KN046Time frame: after completion of the DLT evaluation of the last subject of Phase Ib, up to 28 days
  3. Objective response rateTime frame: until progression or death,whichever came first, assessed up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chi-Mei Medical Center

    Tainan, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.